Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

OptimizeRx Raises FY2025 Sales Guidance from $101.000M-$106.000M to $104.000M-$108.000M vs $103.365M Est

Author: Benzinga Newsdesk | August 07, 2025 03:17pm

2025 Financial Outlook

The Company is increasing its 2025 guidance and expects revenue to be between $104 million and $108 million with Adjusted EBITDA to be between $14.5 million and $17.5 million.

Posted In: OPRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist